TP53 and B-cell chronic lymphocytic leukemia: This underscores the importance of comprehensive genetic testing, utilizing both FISH for del(17p) detection and deep next-generation sequencing for TP53 mutation identification, to refine risk stratification and inform the development of novel therapeutic approaches for CLL patients with complex TP53 aberrations [12].